Pulsetto Triples Revenue in 2025 as Demand for Drug-Free Stress Solutions Surges Worldwide
Mental health disorders affect approximately 970 million people globally. It means 1 in 8 individuals suffer mentally, according to the World Health Organization. While most interventions rely on medication or talk therapy to deal with mental health issues, Pulsetto has taken a different path: using vagus nerve stimulation (VNS) to help people manage stress and improve mental well-being.
Pulsetto closed the first half of 2025 with threefold year-over-year (YoY) growth, which reflects rising global demand for non-invasive mental health tools, according to the company’s founders. After ending 2024 with $10 million in gross revenue – a 3.5x increase over 2023 – the company generated half that amount in Q1 2025 alone. The momentum accelerated in Q2. The growth exceeded previous quarters in many key metrics.
Building on this performance, Pulsetto is now entering its Series A fundraising round to accelerate global expansion and clinical research efforts.
In May 2025, the growth was strongest since the company’s inception. More than 10,000 devices were sold, and the revenue reached $3 million. That was a 39.77% month-over-month increase and a 302.31% rise compared to May 2024.
User engagement and revenue continue to climb
Pulsetto’s companion app has logged over 1.7 million stress-relief sessions in 2025 to date and has already surpassed the 1.3 million sessions recorded in all of 2024. The app now has more than 100,000 monthly active users, which translates to a year-over-year user base increase of 270.6%. Key markets include the United States, Canada, the United Kingdom, Australia, and Germany.
Revenue growth has continued into the second quarter. In just two months, Q2 has brought in approximately €4.47 million ($5.10 million), already exceeding the €4.33 million ($4.94 million) recorded in Q1. Since 2021, revenue increased 56 times.
The company has more than 70 active distributors worldwide.
Expanding into defense and elite sports
In the defense, Pulsetto has adapted its device for trauma and stress-related use cases. For that purpose, in February 2025, the company secured a €2 million investment from Scalewolf, a Lithuanian dual-use technology venture fund. It has since launched a collaboration with Grey Team, a U.S.-based nonprofit supporting the health of military veterans.
Pulsetto is now preparing for clinical research focused on PTSD-specific protocols. It has long-term goals to support both military and first responder communities.
Pulsetto’s VNS technology is being adopted across high-performance and high-stress environments among athletes. In the first half of 2025, NBA All-Star Domantas Sabonis became the company’s official brand ambassador. He regularly demonstrates how VNS can help athletes focus, recover, and stay resilient.
Looking ahead: Pulsetto FIT and global retail expansion
In July, Pulsetto will introduce its next-generation vagus nerve stimulator, “Pulsetto FIT” (V2), alongside new physical retail launches at Selfridges in London and Times Square in New York City. The rollout is backed by ongoing clinical trials, plus studies on postpartum stress and chronic fatigue. The company plans to use the findings to expand its research and marketing strategy.
Pulsetto is moving forward with both B2B and B2C operations. The B2B model is now active in Lithuania and Norway, and new market entries are planned in Ukraine and Poland.
Meanwhile, consumer sales are growing across the DACH region (Germany, Austria, Switzerland), and pilot programs are underway in France, Portugal, Italy, and Sweden.
“As stress becomes a shared global experience, we’re seeing greater urgency for tools that are accessible, evidence-based, and easy to use. Prescription drug use is expected to rise by 400 billion daily doses by 2028. It’s clear people are looking for smarter, drug-free ways to take care of their mental health. Our goal is to offer effective support wherever people are – whether that’s in a clinical setting, on a sports team, or simply at home,” concluded Vitalijus Majorovas, a health tech hacker and co-founder of Pulsetto.